← Back to Search

Brachytherapy

Focal Brachytherapy for Prostate Cancer

Phase < 1

Recruiting

Led By Daniel Song, MD

Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adenocarcinoma of the prostate

Clinical stages (not radiographic stage) T1c - T2a, Nx or N0, Mx or M0

Must not have

History of other malignancy diagnosed within the past 3 years

Prior history of pelvic radiation therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-implant day 30

Awards & highlights

No Placebo-Only Group

Summary

This trial will help the PI learn if 18F-DCFPyl PSMA can help identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease.

Who is the study for?

Men with prostate cancer can join this trial if they have a specific type of tumor (adenocarcinoma), are in fairly good health, and their cancer hasn't spread far. Their prostate must be below a certain size, and they need to be able to handle a special PET scan. They can't participate if they've had pelvic radiation before or other major illnesses that could affect the treatment.

What is being tested?

The study is testing focal brachytherapy guided by an advanced imaging technique using PSMA PET scans. The goal is to target only significant tumors while reducing damage to healthy areas, potentially lowering side effects.

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort from the procedure, urinary issues due to inflammation or damage near the treated area, and typical risks associated with undergoing PET scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with prostate adenocarcinoma.

Select...

My breast cancer is in an early stage and may not have spread to lymph nodes or other parts.

Select...

My prostate cancer has a Gleason score of 6 to 7.

Select...

I can do most of my daily activities without help.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with another cancer within the last 3 years.

Select...

I have had radiation therapy in the pelvic area before.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ post-implant day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~post-implant day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and post-implant day 30 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percent tumor coverage

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Focal brachytherapyExperimental Treatment2 Interventions

Drug: 18F-DCFPyl Other names: PET, PSMA Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy

0 / 6Eligibility criteria met